Panacea Biotec inks Tripartite agreement with Natco Pharma, Breckenridge Pharmaceutical

Panacea Biotec, one of the India’s leading research based pharmaceutical and biotechnology companies, has entered into a tripartite agreement with Natco Pharma and Breckenridge Pharmaceutical for the manufacture and supply of Azacitidine injection for the US market under Breckenridge’s already approved ANDA. Azacitidine is a generic equivalent of Vidaza which is marketed by Celgene Corporateion, US.

As per the terms of the agreement, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec’s facility located at Baddi, Himachal Pradesh, India. Panacea Biotec will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the US.

The application (Prior Approval Supplement) for qualifying Panacea Biotec’s site has been filed with US FDA and approval is expected in due course of time.

Azacitidine is a nucleoside metabolic inhibitor indicated for the treatment of patients with the B myelodyplastic syndrome (MDS), having annual sales of about $ 140 million USD as reported by IMS, MAT, Dec 2017.

Speaking on the occassion, Dr Rajesh Jain, Managing Director, Panacea Biotec says, "We are excited about the collaboration with Natco and Breckenridge on Azacitidine. This collaboration will enable the company to grow its revenues and will also ensure increased capacity utilization of our the state of the art oncology plant at Baddi."

 --------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.